Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Kairos Pharma’s lead asset, ENV-105. The recent positive safety update from the Phase 2 study in patients with metastatic castration-resistant prostate cancer (mCRPC) indicates that ENV-105 is well-tolerated when combined with standard hormone therapy, showing no dose-limiting toxicities or severe adverse events. This positive safety profile supports the continued advancement of ENV-105 in a patient population with significant unmet needs.
Furthermore, the study’s design aims to evaluate the efficacy of ENV-105, with interim data expected in the third quarter of 2025. The primary endpoint focuses on progression-free survival, with the goal of extending it beyond four months in a significant portion of patients. This potential for improved outcomes, alongside the manageable side effects observed, reinforces confidence in the program and suggests a favorable outlook for future regulatory discussions and potential pivotal studies.